Kisunla Side Effects: Risks, Symptoms, and Important Safety Information

Kisunla Side Effects: An Overview

Kisunla side effects are an important consideration for anyone exploring newer treatment options for Alzheimer’s disease. As one of the first amyloid targeting therapies approved to treat early symptomatic Alzheimer’s disease, Kisunla (donanemab azbt) has offered patients and families a new avenue for slowing cognitive decline. But like any powerful biologic medication, it comes with a safety profile that patients, caregivers, and healthcare providers need to understand thoroughly before starting treatment.

This article breaks down what Kisunla is, how it works, and what current medical evidence says about its risks. It also explains ARIA, a condition uniquely associated with amyloid targeting therapies, along with monitoring protocols, risk factors, and situations that call for urgent medical attention. The goal is to give readers a clear, balanced, and medically grounded resource, not personalized medical advice. Anyone considering Kisunla should have an in depth conversation with a qualified neurologist or treating physician about their individual health history.

What Is Kisunla?

Kisunla is the brand name for donanemab azbt, a monoclonal antibody manufactured by Eli Lilly and Company. It received FDA approval in July 2024 for adults with mild cognitive impairment or the mild dementia stage of Alzheimer’s disease, the same population studied in its pivotal clinical trials. Kisunla treatment is not approved for later stages of Alzheimer’s disease, and prescribers are expected to confirm amyloid pathology before initiating therapy.

Kisunla is administered as an intravenous infusion, typically given over approximately thirty minutes once every four weeks. The dose is generally increased gradually over the first several infusions, a titration approach designed to reduce the risk of certain adverse reactions.

Kisunla works by targeting a specific, aggregated form of beta amyloid plaque that builds up in the brains of people with Alzheimer’s disease. By binding to and helping clear these plaques, donanemab is intended to slow the progression of cognitive and functional decline. In the TRAILBLAZER-ALZ 2 clinical trial, Kisunla was shown to significantly slow decline on standardized cognitive and functional scales compared with placebo over 76 weeks, with the most pronounced benefit observed in patients treated earlier in the disease course. Understanding this mechanism is important context for understanding Kisunla side effects, since many of the risks associated with the drug relate directly to how it interacts with amyloid deposits in and around blood vessels in the brain.

Common Kisunla Side Effects

According to the FDA prescribing information and clinical trial data, the most frequently reported Kisunla side effects include amyloid related imaging abnormalities (ARIA), headache, and infusion related reactions. These are the adverse events most consistently identified across the drug’s clinical development program and post marketing safety data.

Common Kisunla side effects reported in trials include:

• Headache, one of the most frequently reported adverse reactions
• Infusion related reactions, including chills, sweating, skin irritation, nausea, chest discomfort, or changes in blood pressure during or shortly after the infusion
• Amyloid related imaging abnormalities (ARIA), which are detected on brain MRI and may or may not cause symptoms
• Fatigue and mild flu like symptoms following infusion

Infusion related reactions were reported in roughly 9 percent of patients in the TRAILBLAZER-ALZ 2 trial, compared with a much lower rate among those receiving placebo. Most of these reactions occurred within the first several infusions and within about 30 minutes of the infusion ending, which is why patients are typically monitored on site after each dose. It is worth noting that Kisunla side effects in elderly patients, who make up the majority of the treated population given the age profile of Alzheimer’s disease, may present somewhat differently or require closer observation due to overlapping health conditions and medications common in older adults.

Serious Kisunla Side Effects

While many Kisunla side effects are mild and manageable, the medication also carries risks that are serious and, in rare cases, life threatening. The FDA prescribing information includes a boxed warning, the agency’s strongest form of warning, specifically addressing the risk of ARIA.

Serious Kisunla side effects and complications identified in clinical trials and post approval data include:

• Symptomatic ARIA, which can involve confusion, headache, visual disturbances, dizziness, or difficulty walking
• Large intracerebral hemorrhages greater than one centimeter, which have occurred in patients treated with this class of medication
• Severe hypersensitivity reactions, including anaphylaxis and angioedema (swelling of the face, lips, or throat)
• Rare cases of intestinal obstruction or perforation
• Neurologic deficits that can closely mimic the symptoms of an ischemic stroke

Hypersensitivity reactions, including anaphylaxis, occurred in approximately 3 percent of patients treated with Kisunla in clinical trials, compared with a much smaller percentage of those on placebo. Because Kisunla complications of this type can escalate quickly, patients are advised to seek emergency care rather than wait to see if symptoms improve on their own.

Understanding ARIA

ARIA, short for amyloid related imaging abnormalities, is the single most important safety concept associated with Kisunla and other amyloid targeting antibody therapies. ARIA is not a side effect in the traditional sense, like nausea or fatigue. Instead, it refers to changes that appear on brain MRI scans, reflecting the way these medications interact with amyloid deposits in the walls of blood vessels within the brain.

ARIA appears in two recognized forms:

• ARIA E, which reflects brain swelling or fluid accumulation (edema) and can appear on MRI scans as swelling or effusions
• ARIA H, which reflects small areas of bleeding in the brain, including microhemorrhages and a pattern called superficial siderosis

According to clinical trial data reviewed by the FDA, ARIA of some form, including asymptomatic cases identified only through imaging, occurred in roughly a third of patients treated with Kisunla, compared with a much smaller percentage of those on placebo. The important nuance here is that Kisunla ARIA is frequently asymptomatic, meaning many patients show these changes on MRI without ever feeling unwell. However, the FDA and Eli Lilly are clear that ARIA can also be serious, symptomatic, and in rare instances fatal. Large intracerebral hemorrhages have been reported in patients on this class of drug, underscoring why routine imaging monitoring is considered essential rather than optional.

Updated dosing schedules introduced after initial approval were shown in later trial data to meaningfully reduce rates of ARIA E while maintaining the drug’s amyloid clearing effect, which is why prescribers now often follow a more gradual titration protocol.

Kisunla and Infusion Related Reactions

Because Kisunla is delivered intravenously, infusion related reactions are a recognized part of its overall safety profile. These reactions typically develop during the infusion itself or within about 30 minutes afterward, and clinical data suggest most occur during the first four treatment sessions rather than later in the treatment course.

Symptoms associated with Kisunla infusion reactions can include chills, sweating, flushing or skin irritation, nausea, vomiting, chest pain, elevated or lowered blood pressure, and general flu like discomfort. In most cases, these reactions are managed by slowing the infusion rate or, if necessary, stopping the infusion and providing supportive treatment. Some patients are premedicated with antihistamines, acetaminophen, or corticosteroids before subsequent infusions if they experienced a reaction previously. Infusion related reactions were also the most common reason patients discontinued treatment in clinical trials, reported in about 4 percent of Kisunla treated patients compared with none on placebo.

Who May Have a Higher Risk of Complications?

Certain patient characteristics are associated with a higher likelihood of Kisunla risks, particularly related to ARIA. Understanding these risk factors is a key part of the informed consent process before starting treatment.

Groups that may face elevated risk include:

• Carriers of the ApoE ε4 gene, particularly those who are homozygous (carrying two copies), who have shown higher rates of ARIA E in clinical trials
• Patients taking anticoagulant or blood thinning medications, which may increase the risk or severity of bleeding related ARIA
• Patients with pre existing cerebral microhemorrhages or certain vascular abnormalities identified on baseline imaging
• Older adults, given that Alzheimer’s disease itself predominantly affects an aging population with a higher likelihood of coexisting health conditions

For this reason, ApoE ε4 genotype testing is commonly discussed with patients before starting Kisunla treatment, even though testing is not always mandatory. Prescribers use this information, along with baseline MRI results, to help evaluate individual Kisunla risks before the first infusion is given.

How Doctors Monitor Patients Taking Kisunla

Because ARIA is often silent in its early stages, monitoring is a cornerstone of safe Kisunla treatment. Standard practice, consistent with FDA prescribing guidance, includes:

• A baseline brain MRI before starting treatment to establish a reference point
• Additional MRI scans at specified intervals during the early months of treatment, when ARIA is most likely to occur
• Careful clinical evaluation if any new neurological symptoms develop, with imaging performed before continuing treatment if ARIA is suspected
• Post infusion observation periods to watch for immediate infusion related reactions
• Ongoing review of concurrent medications, particularly anticoagulants

This structured monitoring schedule is designed to catch asymptomatic ARIA before it progresses and to guide decisions about whether to continue, pause, or discontinue treatment. Patients and caregivers are encouraged to keep track of any new symptoms between appointments and report them promptly, since early detection significantly affects how these events are managed.

When Should You Contact a Doctor?

Recognizing the difference between mild, expected reactions and symptoms requiring urgent evaluation is one of the most important aspects of understanding Kisunla side effects. Patients or caregivers should contact a healthcare provider promptly, or seek emergency care, if any of the following occur:

• New or worsening headache that is severe or does not improve
• Confusion, disorientation, or sudden changes in behavior
• Vision changes, including blurred or double vision
• Difficulty walking, loss of coordination, or new weakness on one side of the body
• Seizures
• Nausea and vomiting that is severe or persistent
• Signs of a severe allergic reaction, such as swelling of the face, lips, tongue, or throat, difficulty breathing, or a widespread rash
• Symptoms that resemble a stroke, since ARIA E can closely mimic ischemic stroke presentation

Because some of these symptoms overlap with a stroke, medical guidance emphasizes that patients should not attempt to determine the cause themselves. Emergency evaluation, including imaging, is the appropriate response any time stroke like symptoms appear in a patient receiving this medication.

Kisunla Safety Information and FDA Guidance

Kisunla FDA approval came with a boxed warning, the agency’s highest level safety alert, specifically addressing the risk of ARIA. The full prescribing information outlines contraindications, warnings, and detailed adverse reaction data drawn from a safety population of more than 2,800 patients who received at least one dose of the medication.

Key points from official Kisunla safety information include:

• Kisunla is contraindicated in patients with known serious hypersensitivity to donanemab azbt or its ingredients
• The prescribing information recommends baseline and periodic MRI monitoring, particularly during the first several months of treatment
• Prescribers are encouraged to discuss ApoE ε4 testing and its implications with patients before treatment begins
• The FDA has continued to review real world safety data, including updated dosing schedules intended to reduce ARIA E rates while preserving efficacy

Patients should always request and review the FDA approved Medication Guide before starting treatment, and should feel free to ask their care team direct questions about how Kisunla warnings apply to their specific health situation.

How Kisunla Compares With Other Alzheimer’s Treatments

Kisunla belongs to a class of Alzheimer’s disease medications known as amyloid targeting monoclonal antibodies, which also includes lecanemab (marketed as Leqembi). Both drugs work by targeting amyloid beta plaques and both carry a boxed warning for ARIA, since this risk appears to be a class effect rather than something unique to a single product.

There are some differences worth noting. Kisunla is administered every four weeks, compared with a more frequent infusion schedule for some alternative therapies. Kisunla’s labeling also allows for the possibility of stopping treatment once amyloid plaques have been substantially cleared, as confirmed by imaging, which is a distinct feature compared with continuous, indefinite dosing regimens used with some other Alzheimer’s drug side effects profiles. Because clinical trials for different drugs are conducted under different conditions and patient populations, the FDA and prescribing physicians caution against directly comparing adverse reaction rates between products. Instead, comparisons should focus on overall safety themes, mechanism of action, dosing convenience, and individual patient risk factors.

Questions to Ask Before Starting Kisunla

Before beginning Kisunla treatment, patients and family members may find it helpful to raise the following questions with their healthcare provider:

• What is my individual risk of ARIA based on my genetics, imaging results, and current medications?
• How often will I need MRI monitoring, and what happens if ARIA is detected?
• Am I currently taking any blood thinning medications that could affect my risk?
• What symptoms should prompt me to call the office immediately versus go to the emergency room?
• How will we decide whether to continue, pause, or stop treatment if side effects occur?
• What support is available if I experience an infusion related reaction?

Bringing a written list of questions to the initial consultation can help ensure that important aspects of Kisunla safety are addressed clearly before treatment begins.

Key Takeaways

Kisunla offers a meaningful treatment option for adults in the early stages of Alzheimer’s disease, but understanding Kisunla side effects is essential before starting therapy. The most common reactions, including headache and infusion-related symptoms, are generally manageable, while ARIA represents the most significant safety concern tied to this class of medication. ARIA is frequently asymptomatic but can, in rare cases, become serious or life threatening, which is why structured MRI monitoring and prompt reporting of new symptoms are built into standard care.

Patients considering Kisunla treatment should review the FDA-approved Medication Guide, discuss personal risk factors such as ApoE ε4 status and blood thinner use with their provider, and understand which symptoms require urgent attention. This article is for general education and does not replace personalized medical advice. Anyone with questions about Kisunla safety, dosing, or side effects should speak directly with a neurologist or treating physician familiar with their full medical history.

Frequently Asked Questions